If you are looking to buy AOD 9604 Peptide AOD 9604, it is best to learn a little about this seldomly ignored miracle worker. Let me introduc
e you to what is now accepted as one of the most effective research peptides known to us at this moment in time.
How long does AOD 9604 take to work?
This hormone is one of the fastest in terms of its ability to show positive results during research.
is a modified form Growth Hormone which is a 191 amino acid peptide. GH is produced by the pituitary gland and is secreted in pulses during the day. It is important to stimulate pituitary gland hormone secretion at various stages during the day. An oral solid GH formulation can provide pulsatile stimulation. AOD 9604 can be administered in this formulation.
Where to Buy AOD9604 5mg
AOD 9604 Growth Hormone is a peptide that is naturally produced in the pituitary gland and in many other organs of the body. It is secreted in pulses during the day. The AOD 9604 from Peptide Sciences is $47.50 and it is without a doubt the best that money can buy!
You can buy AOD 9604 from one of the best USA research peptides manufacturers here at Peptide Sciences. You will not find better quality. Growth hormone stimulates cell growth, multiplication and protein synthesis in many cells and tissues. GH can improve the process of healing in humans. Growth hormone has many positive effects that are important for the proper healing of a wide variety of tissues and organs. It is therefore useful in the treatment of conditions in which cell growth, cell multiplication or increased protein synthesis in the body are desired, such as tissue healing, wound healing, tissue growth, tissue regeneration, tissue re-growth, tissue rejuvenation and in the stimulation of the immune system. Growth hormone is also important for the normal metabolic maintenance and normal growth of the body.
Uses of AOD 9604
Pulsed administration of Growth Hormone has previously been described in patent application WO 89/08539, where GH is administered continuously in pulses for a defined period. This technique of pulsed administration of GH was not specifically aimed at promoting tissue healing and the formulation contained GH in its free form.
GH-secreting adenomas are relatively common tumors of the pituitary gland. When these tumors are large, surgical removal is required. Most of these patients become GH-deficient after the operation and they receive replacement therapy with somatostatin. Somatostatin is a hormone that has the ability to inhibit GH secretion in the pituitary gland and other peripheral tissues.
Buy AOD 9604 Peptide With Caution
The administration of somatostatin (somatotropin release inhibiting factor, SRIF) causes inhibition of the tumor cells of most GH-secreting adenomas. The majority of patients are cured by this procedure. A minority, however, show recurrent tumor after surgery.
GH-secreting adenomas may be treated using several different drug treatment regimens. The most potent drug is bromocriptine, a dopamine agonist that suppresses GH secretion. Other agents which are sometimes used include cyclophosphamide and flurodeoxyglucose.
In other GH-secreting tumors of the pituitary gland, a variety of drugs have been tried to achieve total suppression of the tumor growth, in order to prevent recurrence. In these cases, long-term medication is usually necessary. One such regimen is a combination of bromocriptine and octreotide, another is a combination of interferon and octreotide and a third consists of octreotide alone. Unfortunately, these agents are often associated with side-effects and are not always successful.
GH-secreting adenomas often recur when they are removed and the patient must be re-treated with one of the same or other drugs. For example, a long-acting somatostatin analog may be given as a monthly depot implantation or given by infusion. The recurrence rate with this treatment is high, however.
In other, non-pituitary, growth-dependent cancers, somatostatin and its analogs have proven useful as anticancer drugs. Sustained release formulations have been developed that result in the release of these drugs in a manner that maintains therapeutic drug levels in serum for prolonged periods.
This may allow for administration of higher doses than are currently achievable by daily administration, may extend the interval between administration, and may increase patient compliance.
Somatostatin is disclosed to be administered as a therapeutic agent to treat endocrine tumors, such as tumors derived from the pituitary and pancreas, in U.S. Pat. No. 5,955,487.
For a detailed review of somatostatin analogs used as drugs, see for example, Reubi, Expert Opin. Invest. Drugs, 3:1233-1251 (2004).
Recently, somatostatin analogs have been used in combination with interferon alpha to treat patients with advanced disease, such as with hormone secreting tumors. This is a difficult cancer to treat in that a substantial number of patients with these tumors do not respond to initial therapy. Combination therapy has been found to increase the response rate to 20-40% as compared to the 4-8% with interferon alone. Some combination regimens have been designed to overcome drug resistance and to increase survival. One such combination therapy is described in U.S. Pat. No. 6,187,317.
The present invention discloses a method and composition for treating growth-dependent cancers, such as cancer of the pancreas, and particularly pancreatic cancers. It is generally accepted that most, if not all, pancreatic cancers are driven by an oncogenic KRAS mutation. KRAS is a GTPase protein that is highly associated with poor prognosis, and is considered a critical point of cell transition in cancer. For a review, see Langer, R. et al. “Molecular Targets in Pancreatic Cancer,” J. Biol. Chem., 285:20353-20363 (2010).
The present invention provides a method for treating pancreatic cancer by administering an anti-cancer agent and a pancreatic growth-dependent KRAS inhibitor. The present invention also provides an effective pharmaceutical combination for the treatment of pancreatic cancers.
It is an object of the present invention to provide a novel combination therapy for the treatment of pancreatic cancers. It is also an object of the invention to provide a pharmaceutical combination which exhibits significantly improved survival rates in the treatment of pancreatic cancers. It is a further object of the present invention to provide a pharmaceutical combination exhibiting fewer drug-related toxicities. It is also an object of the invention to provide a method of treating pancreatic cancer which does not require surgical removal of the pancreas, to permit long-term survival of the patient. These and other objects, features and advantages of the present invention will be apparent from the following detailed description of the invention, and from the claims.